We are live on ! Find out more
SGAM

Smith Group Asset Management Portfolio holdings

AUM $2.46B
1-Year Est. Return 57.16%
This Fund
S&P 500
This Quarter Est. Return
+13.92%
1 Year Est. Return
+57.16%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.38B
AUM Growth
-$459M
Cap. Flow
-$743M
Cap. Flow %
-31.14%
Top 10 Hldgs %
33.74%
Holding
419
New
42
Increased
61
Reduced
145
Closed
52

Top Buys

Rank Stock Value
1
EW icon
Edwards Lifesciences
EW
+$31M
2
ROK icon
Rockwell Automation
ROK
+$27.5M
3
CHTR icon
Charter Communications
CHTR
+$23.8M
4
ALK icon
Alaska Air
ALK
+$22.7M
5
TRU icon
TransUnion
TRU
+$21.4M

Top Sells

Rank Stock Value
1
MSFT icon
Microsoft
MSFT
+$59.1M
2
PGR icon
Progressive
PGR
+$57.1M
3
EL icon
Estee Lauder
EL
+$40.6M
4
META icon
Meta Platforms (Facebook)
META
+$33.8M
5
AAPL icon
Apple
AAPL
+$33.4M

Sector Composition

Rank Sector Weight
1 Technology 34.34%
2 Healthcare 16.07%
3 Consumer Discretionary 11.28%
4 Communication Services 10.91%
5 Industrials 10.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MOV icon
226
Movado Group
MOV
$817M
$137K 0.01%
6,314
– –
TITN icon
227
Titan Machinery
TITN
$426M
$137K 0.01%
9,243
– –
ANIP icon
228
ANI Pharmaceuticals
ANIP
$1.74B
$134K 0.01%
2,180
– –
ICPT
229
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$130K 0.01%
1,050
– –
QIWI
230
DELISTED
QIWI PLC
QIWI
$130K 0.01%
6,730
– –
SNBR
231
DELISTED
Sleep Number
SNBR
$129K 0.01%
+2,610
New +$124K
MRTX
232
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$122K 0.01%
950
– –
IMMU
233
DELISTED
Immunomedics Inc
IMMU
$118K ﹤0.01%
5,560
– –
IOVA icon
234
Iovance Biotherapeutics
IOVA
$2.9B
$116K ﹤0.01%
4,190
– –
OSUR icon
235
OraSure Technologies
OSUR
$276M
$112K ﹤0.01%
14,001
– –
AMPY icon
236
Amplify Energy
AMPY
$172M
$106K ﹤0.01%
16,100
– –
PTCT icon
237
PTC Therapeutics
PTCT
$6.23B
$106K ﹤0.01%
2,200
– –
KYNB
238
Kyntra Bio
KYNB
$28.2M
$104K ﹤0.01%
97
– –
ZUMZ icon
239
Zumiez
ZUMZ
$330M
$104K ﹤0.01%
3,020
– –
EBS icon
240
Emergent Biosolutions
EBS
$229M
$97K ﹤0.01%
1,790
– –
HALO icon
241
Halozyme
HALO
$11.6B
$95K ﹤0.01%
5,350
– –
BOLD
242
DELISTED
Audentes Therapeutics, Inc
BOLD
$94K ﹤0.01%
1,570
– –
HBCP icon
243
Home Bancorp
HBCP
$556M
$92K ﹤0.01%
2,340
– –
BSRR icon
244
Sierra Bancorp
BSRR
$516M
$90K ﹤0.01%
3,105
– –
ARCT icon
245
Arcturus Therapeutics
ARCT
$200M
$86K ﹤0.01%
7,890
– –
BGS icon
246
B&G Foods
BGS
$276M
$86K ﹤0.01%
+4,812
New +$81K
RARE icon
247
Ultragenyx Pharmaceutical
RARE
$2.64B
$85K ﹤0.01%
2,000
– –
EGRX
248
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$82K ﹤0.01%
1,372
– –
FOLD
249
DELISTED
Amicus Therapeutics
FOLD
$81K ﹤0.01%
8,280
– –
JPM icon
250
JPMorgan Chase
JPM
$956B
$80K ﹤0.01%
574
-10
-2% -$1.28K
8 9
10
11 12

Similar funds

M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return
QT
Quantbot Technologies New York $2.44B AUM 17.13% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
KFA
Krane Funds Advisors New York $2.44B AUM 12.99% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return

Smith Group Asset Management's Q4 2019 Portfolio in Review

As of Q4 2019, Smith Group Asset Management held 419 positions worth $2.38B, down 16% from $2.84B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Smith Group Asset Management withdrew a net $743M in Q4 2019, closing 52 positions and reducing 145 holdings. Its most notable exit was Estee Lauder, an estimated $40.6M position sold in full.

By sector, the portfolio is most concentrated in Technology at 34% of assets, up from 33% a quarter earlier, followed by Healthcare and Consumer Discretionary.

Against the trend, Smith Group Asset Management opened a new position in Edwards Lifesciences worth $30.9M.

  • Smith Group Asset Management's largest Q4 2019 buy was Edwards Lifesciences: 397,005 shares worth $30.9M.
  • Smith Group Asset Management added most to Huntington Ingalls Industries in Q4 2019, an estimated $18.2M increase.
  • Smith Group Asset Management's biggest Q4 2019 reduction was Microsoft, cutting an estimated $59.1M.
  • Smith Group Asset Management fully exited Estee Lauder in Q4 2019, selling an estimated $40.6M.
  • Smith Group Asset Management's ten largest holdings make up 34% of its $2.38B portfolio in Q4 2019.
  • Smith Group Asset Management opened 42 new positions and closed 52 in Q4 2019.
  • Smith Group Asset Management's portfolio value fell 16% quarter-over-quarter to $2.38B.

Based on Smith Group Asset Management's 13F filing for Q4 2019, filed 4 Feb 2020.